Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 7,500 shares at $69.75 ($533K) on 2026-06-01, disclosed to the SEC on 2026-06-03.
Scheduled sale ($533k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $69.75 | 1,801 | $126K | 23.6% |
| 2 | $70.77 | 2,599 | $184K | 34.5% |
| 3 | $72.06 | 3,100 | $223K | 41.9% |
| Total | $71.06 avg | 7,500 | $533K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $717K | — | Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |